Anti-Müllerian Hormone Levels in Preeclampsia: A Systematic Review of the Literature

  • Vasilios Pergialiotis Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Diamanto Koutaki Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Evangelos Christopoulos-Timogiannakis Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Paraskevi Kotrogianni Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Despina N. Perrea Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Georgios Daskalakis Department of Obstetrics &Gynecology, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Keywords: Preeclampsia, AMH, Gestational Hypertension, Systematic Review

Abstract

Objective: Serum Anti-Müllerian hormone (AMH) has been implicated in the pathogenesis of cardiovascular disease. Its prognostic value in determining the risk of developing preeclampsia remains, to date, unclear. The purpose of the present systematic review is to accumulate current evidence in this field.Materials and methods: We searched Medline (1966–2017), Scopus (2004–2017), Clinicaltrials.gov (2008–2017), EMBASE (1980-2017), LILACS (1986-2017) and Cochrane Central Register of Controlled Trials CENTRAL (1999-2017) databases.Results: Four studies were included in with a total number of 401 women. Among them 146 had preeclampsia while 232 were recruited as normotensive controls. Current data are suggestive of the potential predictive value of serum AMH as its levels seem to be lower among women that develop preeclampsia. One study reported that women with and AMH value below the 10th percentile of the studied population had a 3.3 increased risk of developing preeclampsia (OR 3.3, 95% CI 1.2–8.7, p = 0.01).Conclusion: Taking in mind these findings, future studies are needed in this field to establish optimal cut-off values and evaluate the specificity and sensitivity of this biomarker during the first trimester of pregnancy.

References

References

Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-44.

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.

Bartsch E, Medcalf KE, Park AL, Ray JG, High Risk of Pre-eclampsia Identification G. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016;353:i1753.

Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30 Suppl A:S32-7.

Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Schielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv 2011;66:225-39.

Deffieux X, Antoine JM. [Inhibins, activins and anti-Mullerian hormone: structure, signalling pathways, roles and predictive value in reproductive medicine]. Gynecol Obstet Fertil 2003;31:900-11.

Ledger WL. Clinical utility of measurement of anti-mullerian hormone in reproductive endocrinology. J Clin Endocrinol Metab 2010;95:5144-54.

de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative

marker for ovarian aging. Fertil Steril 2002;77:357-62.

Qayyum R, Akbar S. Serum anti-mullerian hormone and all-cause mortality in men. Endocrine 2016;54: 225-31.

Dennis NA, Jones GT, Chong YH, van Rij AM, McLennan IS. Serum anti-Mullerian hormone (AMH) levels correlate with infrarenal aortic diameter in healthy older men: is AMH a cardiovascular hormone? J Endocrinol 2013;219:13-20.

Koninger A, Kauth A, Schmidt B, Schmidt M, Yerlikaya G, Kasimir-Bauer S, et al. Anti-Mullerian-hormone levels during pregnancy and postpartum. Reprod Biol Endocrinol 2013;11:60.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

Al-Moghrabi D, Salazar FC, Pandis N, Fleming PS. Compliance with removable orthodontic appliances and adjuncts: A systematic review and meta-analysis. Am J Orthod Dentofacial Orthop 2017;152:17-32.

Agabain E, Mohamed H, Elsheikh AE, Hamdan HZ, Adam I. Maternal serum anti-Mullerian hormone in Sudanese women with preeclampsia. BMC Res Notes 2017;10:217.

Tokmak A, Guney G, Aksoy RT, Guzel AI, Topcu HO, Kececioglu TS, et al. May maternal anti-mullerian hormone levels predict adverse maternal and perinatal outcomes in preeclampsia? J MaternFetal NeonatalMed 2015;28:1451-6.

Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC. Maternal serum anti-Mullerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia. J Matern Fetal Neonatal Med 2015;28:865-8.

Shand AW, Whitton K, Pasfield A, Nassar N, McShane M, Han X, et al. Evaluation of anti-Mullerian hormone in the first trimester as a predictor for hypertensive disorders of pregnancy and other adverse pregnancy outcomes. Aust N Z J Obstet Gynaecol 2014;54:244-9.

Bernard V, Donadille B, Zenaty D, Courtillot C, Salenave S, Brac de la Perriere A, et al. Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. Hum Reprod 2016;31:782-8.

Yarde F, Maas AH, Franx A, Eijkemans MJ, Drost JT, van Rijn BB, et al. Serum AMH levels in women with a history of preeclampsia suggest a role for vascular factors in ovarian aging. J Clin Endocrinol Metab 2014;99:579-86.

Bhide P, Vartun A, Aune B, Flo K, Basnet P, Acharya G. Ovarian reserve in women with a previous history of severe pre-eclampsia. Arch Gynecol Obstet 2017;295:233-8.

Vartun A, Aune B, Flo K, Acharya G. PP079. Ovarian reserve and function is preserved following severe preeclampsia. Pregnancy Hypertens 2013;3:96.

Anderson RA, Nelson SM, Wallace WH. Measuring anti-Mullerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas 2012;71:28-33.

Appt SE, Chen H, Clarkson TB, Kaplan JR. Premenopausal antimullerian hormone concentration is associated with subsequent atherosclerosis. Menopause 2012;19:1353-9.

Chong YH, Dennis NA, Connolly MJ, Teh R, Jones GT, van Rij AM, et al. Elderly men have low levels of anti-Mullerian hormone and inhibin B, but with high interpersonal variation: a cross-sectional study of the sertoli cell hormones in 615 community-dwelling men. PLoS One 2013;8:e70967.

Seifer DB, MacLaughlin DT, Cuckle HS. Serum mullerian-inhibiting substance in Down's syndrome

pregnancies. Hum Reprod 2007;22:1017-20.

Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 2013;28:1077-83. doi:10.1093/humrep/det015

Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol 2011;204:558 e1-6.

Figueroa-Vega N, Moreno-Frias C, Malacara JM. Alterations in adhesion molecules, pro-inflammatory cytokines and cell-derived microparticles contribute to intima-media thickness and symptoms in postmenopausal women. PLoS One 2015;10:e0120990.

Published
2018-06-10
How to Cite
1.
Pergialiotis V, Koutaki D, Christopoulos-Timogiannakis E, Kotrogianni P, Perrea DN, Daskalakis G. Anti-Müllerian Hormone Levels in Preeclampsia: A Systematic Review of the Literature. JFRH. 11(4):179-84.
Section
Review Articles